Adiposs

Geneva, Switzerland · Founded 2004 · Privately Held (backing)

Developer of medical imaging products and technologies designed for the early detection of cachexia, a devastating body-wasting syndrome. Adiposs is based in Geneva, Switzerland and was founded in 2004. Its last reported valuation was $48.8 million in Dec 2021. It has raised $7.3 million.

Last reported valuation
$48.8M
Oct 2026
Priced at
—
Total raised
$7.3M
Last round
—

Adiposs key facts

as of Oct 2026
  • Developer of medical imaging products and technologies designed for the early detection of cachexia, a devastating body-wasting syndrome.
  • Adiposs is valued at approximately $48.8M as of Oct 2026 (last reported valuation).
  • It has raised $7.3M; the latest was Later Stage VC ($4.9M) in Jul 2025.
  • Notable investors include MassChallenge, Venture Kick, Kickfund, Kingbridge, CR Ventures (Acquired in 2022) — 11 tracked in total.
  • Status: Privately Held (backing).
Last reported valuation
LOW confidence
$48.8M

Adiposs's last reported valuation, Dec 2021. Nothing priced has surfaced since.

set by last reported valuationas of Oct 2026question about this number?
Free account
More of Adiposs with a free account
  • ·The complete investor list: 11 names
  • ·Watch Adiposs: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Adiposs funding rounds

No rounds on record

No funding rounds for Adiposs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Adiposs valuation

Adiposs's last reported valuation was $48.8 million in Dec 2021. No priced round, secondary trade or fund mark has surfaced since.

Adiposs investors

11 investors are on record for Adiposs, including MassChallenge, Venture Kick, Kickfund and Kingbridge.

About Adiposs

Developer of medical imaging products and technologies designed for the early detection of cachexia, a devastating body-wasting syndrome. The company's CT contrast product can detect body wasting early, before weight loss, a year earlier, enabling hospitals and healthcare providers to detect cancer early, improve patients' quality of life, and give them a better chance to survive cancer and other chronic diseases.

Sector
Healthcare
HQ
Geneva, Switzerland
Founded
2004
Employees
6
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.